Published in Hepatitis Weekly, April 8th, 1996
AMBA's technology creates an opportunity to produce safe, cost-effective, and highly efficacious alpha interferon, where existing technologies fall short in at least one of these important criteria. Currently alpha interferon is approved for a variety of indications including Hepatitis C and certain cancers.
The product is manufactured through recombinant means or as a "natural" product, consisting of many of the over 20 subtypes of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.